Opinion|Videos|October 18, 2024
Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
Panelists discuss how patient-specific factors such as disease status, overall health, support systems, and treatment history are crucial considerations when determining readiness for potential transition to community settings for ongoing care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What patient specific factors might you consider?
- Are there any criteria that patients need to meet to be ready to move to a community setting? Does this vary between community settings?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5